Biotechnology company focusing on medical and scientific re-emergence of psychedelics and psychedelic-infused therapies Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF) announced having been granted a conditional approval to list its common shares on the Toronto Stock Exchange (TSX).
This will be an up-listing from Canadian Securities Exchange (CSE) which the shares are currently listed on. However, this up-listing will be subject to certain regulatory requirements in accordance with the terms and conditions of Toronto Stock Exchange.
If Field Trip will meet all the conditions and requirements in the up-listing letter it received from TSX on May 27, then it will get listed on TSX soon. After securing the final approval, the company will issue a public statement to its shareholders who are eagerly waiting for the company’s shares to start trading on TSX.
“Receiving conditional acceptance to move to Canada’s largest exchange is a significant milestone for Field Trip and the emerging psychedelics industry more broadly. While our listing on the TSX will provide greater visibility for Field Trip in the markets and broaden our access to additional Canadian and international investors, we continue to work towards further enhancing liquidity for global investors in Field Trip, including exploring cross-listings onto US exchanges,” said the company’s CEO.
Following the up-listing, shares of the company will be delisted from Canadian Securities Exchange.
